

Isofol to present at the 10th Annual Biotech Showcase Conference

January 4 2017

Isofol Medical AB (publ), a clinical oncology company, announces that Chief Executive Officer Anders Rabbe and Chief Commercial Officer Sven Erickson will present at the 10th Annual Biotech Showcase Conference, to be held during the 8-10th of January in San Francisco, USA. The event is a networking conference dedicated to providing biotechnology companies with an opportunity to meet with, investors and pharmaceutical executives, during the course of the largest annual healthcare investor conference, the 36th Annual J.P. Morgan Healthcare Conference.

Sven Erickson, CCO of Isofol Medical, commented: *"The JP Morgan Healthcare event and Biotech Showcase Conference are the centers of pharma innovation and business, an excellent environment for discussions with partners and investors about next generation colorectal cancer treatment and the upcoming pivotal efficacy trial of Modufolin®(Arfolitixorin). We have an exciting agenda, meeting both with potential partners and investors."*

Presentation information

Venue: Hilton, Union Square, San Francisco

Date: Wednesday, 10 January 2018

Time: 10:00 a.m. PST

Conference Hall: Yosemite - A

For more information, please contact:

Anders Rabbe, CEO, Isofol Medical AB

E-mail: anders.rabbe@isofolmedical.com

Phone: +46 (0)707 646 500

Sven Erickson, CCO, Isofol Medical AB

Email: sven.erickson@isofolmedical.com

Phone:(+46)722 006 090

About Modufolin®

Modufolin® (Arfolitixorin), is a novel folate-based compound developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment. It is the key active metabolite of the widely used folate-based drugs leucovorin and levoleucovorin. As Modufolin® does not require metabolic activation to exert its effect, Modufolin® is suitable for all patients irrespective of their capacity to activate folates. Modufolin® is currently being evaluated in a clinical Phase II study.

About Isofol Medical AB

Isofol Medical AB (publ) is a clinical stage oncology company developing Modufolin®(Arfolitixorin) as a first-line treatment of metastatic colorectal cancer and as a rescue drug after high-dose methotrexate treatment in osteosarcoma. Through a worldwide exclusive license agreement, Isofol Medical holds the rights to commercialise Modufolin®(Arfolitixorin) with access to the unique patented production process and the production capabilities of Merck KGaA, Darmstadt, Germany. Isofol Medical AB (publ) is traded on the Nasdaq First North Premier. Certified Adviser is FNCA Sweden AB.

www.isofol.se